Deans' stroke musings: Viz.ai and Medtronic to collaborate on improving post-cryptogenic stroke care in USA

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Friday, March 29, 2024

Viz.ai and Medtronic to collaborate on improving post-cryptogenic stroke care in USA

Why should we be listening to this? 'care'; NOT RECOVERY OR RESULTS! I expect hospitals to deliver recovery, NOT 'CARE'

Viz.ai and Medtronic to collaborate on improving post-cryptogenic stroke care in USA

Viz.ai has announced a strategic collaboration with Medtronic to improve the coordination of cryptogenic stroke patient care between neurology and cardiology teams.

For stroke patients who are at risk of atrial fibrillation (AF) post-stroke and may need additional cardiac monitoring, stroke care teams in the USA will have the opportunity to use the Viz Connect solution—a software tool that automates the communication across disciplines, including neurology and cardiology.

Recent clinical study results indicate that both community hospitals and academic centres are in need of stronger, standardised care pathways between neurology and cardiology to ensure that stroke patients receive guideline-directed therapy, as stated in a recent press release. One example the release cites is the DiVERT Stroke clinical study, in which only 16% of stroke patients from community hospitals and 34% of patients at academic centres received a cardiology consult.

“Through our collaboration with Medtronic, we have the opportunity to bring cardiology and neurology closer together by using software tools that help facilitate stroke patient care,” said Chris Mansi, chief executive officer and co-founder at Viz.ai. “We are confident this collaboration will help more patients get the continuity of care and treatment they need to reduce secondary stroke recurrence.”

According to Viz.ai, Viz Connect has demonstrated impact on improving patient access to cardiac care after a cryptogenic stroke—strokes with an unknown cause, but that impact close to 800,000 people each year in the USA, require cardiac workup, and are followed by a second stroke within two years in roughly 20% of cases. Examples of Viz Connect’s impact detailed in the release include an average increase of more than 50% in in-patient cardiology follow-up, and an average time of under five minutes from when the notification is sent from neurology to when it is reviewed by a cardiologist.

“We look forward to helping hospital care teams more easily get patients to the right specialist at the right time,” said Stacey Churchwell, vice president and general manager, Cardiovascular Diagnostics and Services within the Cardiac Rhythm Management business, which is part of the Cardiovascular Portfolio at Medtronic.